NCT02186847 2025-10-09
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NRG Oncology
Phase 2 Completed
Clinical Trials
56 trialsNCT03184571 2025-09-25
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
Phase 2 Completed
NCT00334815 2025-08-24
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04533451 2025-06-13
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT03845296 2025-05-21
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2 Completed
NCT05012397 2024-10-17
Milademetan in Advanced/Metastatic Solid Tumors
Rain Oncology Inc
Phase 2 Terminated
NCT02264210 2024-09-25
CORIN
Sun Yat-sen University
Phase 2 Completed
NCT02759835 2024-06-07
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04027946 2024-04-16
LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02414139 2024-03-20
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Novartis
Phase 2 Completed
NCT00828009 2023-07-07
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00080938 2023-06-29
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00970684 2022-08-16
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03041181 2022-07-11
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00979212 2022-06-15
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01935336 2022-02-11
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
University of Colorado, Denver
Phase 2 Completed
NCT02303977 2021-09-29
Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00438204 2021-04-13
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT01610336 2021-04-08
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Phase 2 Completed
NCT02450903 2021-03-30
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Novartis
Phase 2 Completed
NCT02276027 2020-12-16
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Novartis
Phase 2 Completed
NCT00950365 2020-09-16
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
Albert Einstein College of Medicine
Phase 2 Completed
NCT01218516 2020-08-20
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Morphotek
Phase 2 Completed
NCT00436332 2020-04-02
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
SWOG Cancer Research Network
Phase 2 Completed
NCT00445848 2020-03-05
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00960999 2020-03-04
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00661193 2020-02-20
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02134912 2020-02-20
S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
SWOG Cancer Research Network
Phase 2 Terminated
NCT02285855 2020-01-06
Metformin in Non Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00126581 2019-08-07
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01646125 2019-07-24
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Novartis
Phase 2 Terminated
NCT00234052 2019-06-04
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Northwestern University
Phase 2 Completed
NCT02839681 2019-05-21
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00551369 2019-04-30
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01685138 2019-03-26
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Novartis
Phase 2 Completed
NCT00754923 2019-03-06
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00087438 2019-01-16
Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01578551 2018-12-19
Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT01557959 2018-06-29
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00955305 2018-06-06
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00553462 2018-01-31
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00281827 2017-12-28
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT00365547 2017-12-28
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00526890 2017-11-28
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01344824 2017-10-30
Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00550537 2017-06-08
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00454194 2017-03-21
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00776100 2017-03-06
Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00798603 2017-01-25
Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01294306 2016-11-29
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
National Cancer Institute (NCI)
Phase 2 Completed